Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

A novel melanocortin fusion protein inhibits fibrinogen oxidation and degradation during trauma-induced coagulopathy

Chang Yeop Han, Xu Wang, Kristyn M. Ringgold, Jennifer C. Bennett, Alexander E. St. John, Ronald Berenson, Susan A. Stern, Nathan J. White

Blood (2023) 142 (8): 724–741.

https://doi.org/10.1182/blood.2022019164

Published: 2023

Includes: Supplemental data

Journal Articles

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Gary J. Schiller, Sascha A. Tuchman, Natalie Callander, Muhamed Baljevic, Adrianna C Rossi, Rami Kotb, Darrell J White, Nizar J. Bahlis, Heather J. Sutherland, Sumit Madan, Richard Leblanc, Christopher P. Venner, William I. Bensinger, Dane R. Van Domelen, Chris Zhang, Ohad S. Bentur, Brea Lipe

Blood (2022) 140 (Supplement 1): 10050–10053.

https://doi.org/10.1182/blood-2022-158011

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Richard Leblanc, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Michael P. Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha L Louzada, Hira S Mian, Darrell J White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7192–7194.

https://doi.org/10.1182/blood-2022-158679

Published: 2022

Journal Articles

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10002–10004.

https://doi.org/10.1182/blood-2022-163661

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Suzanne Trudel, Arleigh McCurdy, Molei Fu, Heather J. Sutherland, Martha L Louzada, Michael P. Chu, Darrell J White, Hira S Mian, Rami Kotb, Ibraheem Othman, Moustafa Kardjadj, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7306–7307.

https://doi.org/10.1182/blood-2022-160445

Published: 2022

Journal Articles

What causes malaria anemia?

Nicholas J. White

Blood (2022) 139 (15): 2268–2269.

https://doi.org/10.1182/blood.2021015055

Published: 2022

Journal Articles

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Hira S Mian, Richard Leblanc, Martha L Louzada, Esther Masih-Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Michael Sebag, Darrell J White, Muhammad Aslam, Kevin W Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna E. Reece

Blood (2021) 138 (Supplement 1): 4721.

https://doi.org/10.1182/blood-2021-148191

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood (2021) 138 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2021-150232

Published: 2021

Journal Articles

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, Arleigh McCurdy, Heather J. Sutherland, Martha L Louzada, Christopher P. Venner, Hira S Mian, Rami Kotb, Ibraheem Othman, Fernando Camacho, Engin Gul, Donna E. Reece, Darrell J White, Molei Fu

Blood (2021) 138 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2021-147101

Published: 2021

Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Blood (2021) 138 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2021-146324

Published: 2021

Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2021) 137 (26): 3616–3628.

https://doi.org/10.1182/blood.2020008787

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139858

Published: 2020

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-141087

Published: 2020

Journal Articles

Targeted Deep Sequencing As a Clinically Effective Approach to Profile the Mutational Landscape in Multiple Myeloma

Samuel Cutler, MSc, Dan Gaston, PhD, Philipp Knopf, Andrea Thoni, MD, Nicholas Allen Forward, MDMSc,FRCPC, Darrell J White, MD, Julie Wagner, PhD, Marissa Goudie, Manal Elnenaei, MBChB, PhD FRCPath

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137754

Published: 2020

Journal Articles

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-140141

Published: 2020

Journal Articles

Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137183

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-142800

Published: 2020

NARROW

A novel melanocortin fusion protein inhibits fibrinogen oxidation and degradation during trauma-induced coagulopathy

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

What causes malaria anemia?

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Targeted Deep Sequencing As a Clinically Effective Approach to Profile the Mutational Landscape in Multiple Myeloma

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only